**Supplementary Table S3: Univariate and multivariate analysis of OS according to TMB and clinical features**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | Category | Univariate | Multivariate |
| **HR** | **95% CI** | **P\*** | **HR** | **95% CI** | **P\*** |
| **TMB** | low vs high | 3.77 | 1.25 | 11.32 | 0.018 | 3.39 | 1.11 | 10.30 | 0.032 |
| **Age** | ≥ 65 vs < 65 | 1.30 | 0.57 | 2.95 | 0.537 |  |  |  |  |
| **Sex** | Female vs Male | 1.80 | 0.79 | 4.11 | 0.165 |  |  |  |  |
| **ECOG PS** | 1 vs 0 | 3.19 | 1.35 | 7.49 | 0.008 | 3.06 | 1.29 | 7.24 | 0.011 |
| **Previous treatment regimens** | ≥ 2 vs 1 | 1.19 | 0.50 | 2.86 | 0.692 |  |  |  |  |
| **Liver metastasis** | Yes vs No | 1.90 | 0.74 | 4.84 | 0.180 |  |  |  |  |
| **Lung metastasis** | Yes vs No | 0.78 | 0.23 | 2.62 | 0.683 |  |  |  |  |
| **Lymph node metastasis** | Yes vs No | 1.11 | 0.38 | 3.27 | 0.851 |  |  |  |  |
| **Peritoneal dissemination** | Yes vs No | 1.19 | 0.52 | 2.71 | 0.676 |  |  |  |  |
| **Number of metastatic organs** | ≥ 2 vs 1 | 1.77 | 0.77 | 4.10 | 0.182 |  |  |  |  |
| **Treatment** | Pembrolizumabwith napabucasinvsanti-PD-1 monotherapy | 0.44 | 0.13 | 1.50 | 0.192 |  |  |  |  |

\*P values were calculated using the Cox proportional hazards model.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; CI, confidence interval; TMB, tumor mutational burden